Evaluation and Management of Sarcoidosis‑Related Hearing Loss

Initial Evaluation

Patients with sarcoidosis who present with hearing loss should undergo urgent audiologic assessment to differentiate sensorineural from conductive loss, because neurosarcoidosis‑related sensorineural loss is steroid‑responsive and treatment delays can cause permanent impairment. American Academy of Otolaryngology‑Head and Neck Surgery recommendation. 1

Perform bedside tuning‑fork (Weber and Rinne) testing immediately; the results direct the entire subsequent management pathway by distinguishing conductive from sensorineural loss. AAO‑HNS guidance. 3
If sudden sensorineural hearing loss (SSNHL) is suspected, obtain comprehensive audiometry within 72 hours. SSNHL is defined as a ≥30 dB loss at three consecutive frequencies that develops over a 72‑hour period. AAO‑HNS protocol. 4
Systematically assess for bilateral ear involvement and vestibular symptoms, since sarcoidosis may produce bilateral vestibular loss, fluctuating hearing loss, and vertigo. AAO‑HNS observation. 2

Measure serum angiotensin‑converting enzyme (ACE) level; elevation supports sarcoidosis, but a normal level does not exclude neurosarcoidosis. AAO‑HNS recommendation. 1
Consider a Gallium‑67 scan to evaluate systemic sarcoid disease burden. AAO‑HNS suggestion. 2
Do not obtain routine non‑contrast head CT for these patients, as it lacks the resolution needed for sensorineural pathology and adds unnecessary radiation exposure. AAO‑HNS contraindication. 4

Schedule repeat audiometry at 6 months after initial diagnosis to gauge treatment response and identify any progression. AAO‑HNS follow‑up guideline. 3
Re‑evaluate patients for other systemic sarcoidosis manifestations—including pulmonary, ocular, and additional cranial neuropathies—during follow‑up visits. AAO‑HNS comprehensive care recommendation. 2